دورية أكاديمية
أعرض في EDS

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer.
المؤلفون: Luining WI; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands., Hagens MJ; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.; Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Meijer D; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands., Ringia JB; Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., de Weijer T; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Bektas HO; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Ettema RH; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands., Knol RJJ; Department of Nuclear Medicine, Noordwest Hospital, Alkmaar, The Netherlands., Roeleveld TA; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.; Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department Urology, Noordwest Hospital, Alkmaar, The Netherlands., Srbljin S; Department of Nuclear Medicine, Zaans Medical Center, Zaandam, The Netherlands., Weltings S; Department of Urology, Zaans Medical Center, Zaandam, The Netherlands., Koppes JCC; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, The Netherlands., van Moorselaar RJA; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands., van Leeuwen PJ; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.; Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Oprea-Lager DE; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, The Netherlands., Vis AN; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
المصدر: European urology open science [Eur Urol Open Sci] 2023 Dec 22; Vol. 59, pp. 55-62. Date of Electronic Publication: 2023 Dec 22 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101771568 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-1683 (Electronic) Linking ISSN: 26661683 NLM ISO Abbreviation: Eur Urol Open Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2020]-
مستخلص: Background and Objectives: The association between prostate-specific antigen (PSA) level and probability of metastatic disease on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has not yet been established in patients with newly diagnosed prostate cancer (PCa). Our objective was to assess the probability of metastatic disease within different PSA ranges using PSMA PET/CT for initial staging of PCa, and to identify both the anatomical distribution and the predictors of metastases on PSMA PET/CT.
Methods: In total, 2193 patients with newly diagnosed PCa were retrospectively studied. PSMA PET/CT was performed for staging purposes between January 2017 and May 2022. The proportion of patients with PSMA-avid metastases, stratified by PSA level, was studied. A vast majority of patients in whom at least one high-risk prognostic factor was present underwent PSMA PET/CT. A multivariable logistic regression analysis was performed to identify the predictors of metastases on PSMA PET/CT using clinical, biochemical, radiological, and pathological variables.
Key Findings and Limitations: The median PSA level at PSMA PET/CT was 14.1 ng/ml. Any metastatic disease (miN1-M1a-c) was observed in 34.7% (763/2193) of all patients and distant metastases (miM1a-c) in 25.4% (557/2193) of patients. The presence of any metastatic disease increased with PSA levels, being 15.4% in men with PSA levels <10 ng/ml and 87.5% in men with PSA levels >100 ng/ml. The multivariable logistic regression analysis found significant associations between the presence of any metastatic disease and PSA subgroups, clinical tumor stage ≥T2, grade group >3, and radiological tumor stage ≥T3b.
Conclusions and Clinical Implications: This is the first large epidemiological study in patients with PCa demonstrating the association between PSA subgroups and metastatic disease on modern imaging PSMA PET/CT. Data from this study can be used to counsel patients on the probability of metastatic disease at the time of PSA screening and to provide guidance on existing guidelines.
Patient Summary: The prostate-specific antigen level could be used to assess the risk of metastases on prostate-specific membrane antigen positron (PSMA) emission tomography/computed tomography (PET/CT). This knowledge is valuable for selecting patients who will benefit most from metastatic screening with PSMA PET/CT.
(© 2023 The Author(s).)
References: Lancet. 2020 Apr 11;395(10231):1208-1216. (PMID: 32209449)
EJNMMI Res. 2021 Dec 20;11(1):128. (PMID: 34928437)
J Urol. 2018 Mar;199(3):683-690. (PMID: 29203269)
J Nucl Med. 2021 Feb;62(2):214-220. (PMID: 32444374)
Am J Surg Pathol. 2016 Feb;40(2):244-52. (PMID: 26492179)
Eur Urol. 2023 May;83(5):405-412. (PMID: 36935345)
World J Urol. 2021 Jul;39(7):2439-2446. (PMID: 33079250)
EJNMMI Res. 2016 Dec;6(1):40. (PMID: 27142881)
Eur Urol. 2020 Apr;77(4):403-417. (PMID: 30773328)
Semin Nucl Med. 2024 Jan;54(1):39-45. (PMID: 37487824)
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4495-4507. (PMID: 34136957)
J Nucl Med. 2023 Aug;64(8):1238-1243. (PMID: 37385673)
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494. (PMID: 34120201)
Eur Urol. 2019 Sep;76(3):340-351. (PMID: 30898406)
Eur Urol Oncol. 2021 Aug;4(4):635-644. (PMID: 32675047)
Nucl Med Commun. 2017 Nov;38(11):956-963. (PMID: 28922335)
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638. (PMID: 33604691)
BJU Int. 2019 Sep;124(3):401-407. (PMID: 31141284)
Pharmaceuticals (Basel). 2017 Sep 27;10(4):. (PMID: 28953234)
Eur Urol. 2021 Feb;79(2):243-262. (PMID: 33172724)
J Nucl Med. 2021 Oct;62(10):1422-1429. (PMID: 33547211)
J Nucl Med. 2022 Oct;63(10):1531-1536. (PMID: 36008118)
فهرسة مساهمة: Keywords: Metastatic disease; Prostate cancer; Prostate-specific antigen; Prostate-specific membrane antigen positron emission tomography/computed tomography
تواريخ الأحداث: Date Created: 20240201 Latest Revision: 20240202
رمز التحديث: 20240202
مُعرف محوري في PubMed: PMC10829602
DOI: 10.1016/j.euros.2023.12.001
PMID: 38298765
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-1683
DOI:10.1016/j.euros.2023.12.001